Topic: product and process development
In part two of this webinar series on the 505(b)(2) pathway, Ken delves deeper into IND-enabling activities including CMC, toxicology and PK/PD.
The Discovery Labs is forming a $500 million healthcare and life sciences tech co-working community at a former GSK facility in Pennsylvania.
CDMO Lonza is getting into the gut bacteria filed with a joint venture to produce live biotherapeutic products for trials and development.
This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2), the pathway of choice.